Security key
98422T100
Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO)
CUSIP: 98422T100
Q3 2024 13F Holders as of 30 Sep 2024
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 6,426,426
- Total 13F shares
- 15,911,945
- Share change
- +1,434,916
- Total reported value
- $12,534,583
- Price per share
- $0.79
- Number of holders
- 32
- Value change
- +$1,128,156
- Number of buys
- 13
- Number of sells
- 7
Report period
Q3 2024
Institutions
32
Top holders
10
XLO full security history
Newer quarter: Q4 2024
Previous quarter: Q2 2024
Xilio Therapeutics, Inc. SEC filings
Xilio Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 98422T100
Recent filing periods:
Top shareholders of XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC |
13F
3/4/5
|
Company · 10%+ Owner |
59%
|
3,785,450
|
$3,586,714 | — | 30 Jun 2024 | |
| Rock Springs Capital Management LP |
13F
3/4/5
|
Company · 10%+ Owner |
47%
|
3,003,259
|
$2,845,588 | — | 30 Jun 2024 | |
| TAKEDA PHARMACEUTICAL CO LTD |
13F
3/4/5
|
Company · 10%+ Owner |
23%
|
1,475,121
|
$1,398,415 | — | 30 Jun 2024 | |
| RiverVest Venture Management LLC |
13F
|
Company |
22%
|
1,441,444
|
$1,365,768 | — | 30 Jun 2024 | |
| FMR LLC |
3/4/5
13F
|
Other* · Company |
22%
from 13F
|
1,907,670
|
$1,583,366 | — | 26 Oct 2021 | |
| MORGAN STANLEY |
13F
|
Company |
17%
|
1,112,740
|
$1,054,321 | — | 30 Jun 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
14%
|
902,531
|
$855,148 | — | 30 Jun 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
4.6%
|
295,000
|
$279,513 | — | 30 Jun 2024 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
4.2%
|
272,486
|
$258,180 | — | 30 Jun 2024 | |
| FIL Ltd |
13F
3/4/5
|
Company · Other* |
3.4%
|
218,705
|
$207,223 | — | 30 Jun 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.8%
|
182,855
|
$173,289 | — | 30 Jun 2024 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.1%
|
71,081
|
$67,349 | — | 30 Jun 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
1%
|
66,418
|
$62,931 | — | 30 Jun 2024 | |
| STATE STREET CORP |
13F
|
Company |
0.68%
|
43,390
|
$41,112 | — | 30 Jun 2024 | |
| SevenBridge Financial Group, LLC |
13F
|
Company |
0.64%
|
41,000
|
$37,179 | — | 30 Jun 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.61%
|
39,208
|
$37,150 | — | 30 Jun 2024 | |
| RAYMOND JAMES & ASSOCIATES |
13F
|
Company |
0.6%
|
38,825
|
$36,787 | — | 30 Jun 2024 | |
| XTX Topco Ltd |
13F
|
Company |
0.52%
|
33,289
|
$31,541 | — | 30 Jun 2024 | |
| Avantax Planning Partners, Inc. |
13F
|
Company |
0.39%
|
25,000
|
$23,688 | — | 30 Jun 2024 | |
| TWO SIGMA SECURITIES, LLC |
13F
|
Company |
0.21%
|
13,271
|
$12,574 | — | 30 Jun 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.19%
|
12,205
|
$11,564 | — | 30 Jun 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.19%
|
11,925
|
$11,299 | — | 30 Jun 2024 | |
| Dunhill Financial, LLC |
13F
|
Company |
0.16%
|
10,274
|
$9,735 | — | 30 Jun 2024 | |
| Pinnacle Financial Group, LLC / IL |
13F
|
Company |
0.16%
|
10,000
|
$9,475 | — | 30 Jun 2024 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.07%
|
4,207
|
$3,988 | — | 30 Jun 2024 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
0.02%
|
1,500
|
$1,421 | — | 30 Jun 2024 | |
| Key FInancial Inc |
13F
|
Company |
0.01%
|
830
|
$786 | — | 30 Jun 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.01%
|
692
|
$656 | — | 30 Jun 2024 | |
| UBS Group AG |
13F
|
Company |
0%
|
201
|
$191 | — | 30 Jun 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
59
|
$56 | — | 30 Jun 2024 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0%
|
4
|
$4 | — | 30 Jun 2024 | |
| Yekaterina Chudnovsky |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
7,000,000
|
$5,320,000 | — | 07 Jun 2024 | |
| SV7 Impact Medicine Fund LP |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
3,227,264
|
$2,678,630 | — | 26 Oct 2021 | |
| James E. Flynn |
3/4/5
|
Possible Member of 10% Group, 10%+ Owner |
—
class O/S missing
|
2,287,944
|
$1,898,994 | — | 26 Oct 2021 | |
| Atlas Venture Fund XI, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,754,109
|
$1,762,629 | — | 08 Feb 2024 | |
| RiverVest Venture Fund IV, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,441,444
|
$1,196,399 | — | 26 Oct 2021 | |
| BAY CITY CAPITAL LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,129,490
|
$937,477 | — | 26 Oct 2021 | |
| Merck KGaA |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
680,825
|
$565,085 | — | 26 Oct 2021 | |
| Alexandria Venture Investments, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
166,423
|
$138,131 | — | 26 Oct 2021 | |
| Simon M. Tomlinson |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
131,117
|
$108,827 | — | 21 Oct 2021 | |
| John Charles Williams |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
100,080
|
$83,066 | — | 21 Oct 2021 | |
| Of Ulrich Rodeck Estate |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
100,080
|
$83,066 | — | 21 Oct 2021 | |
| Timothy P. Clackson |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
90,956
|
$75,493 | — | 21 Oct 2021 | |
| Rachel Humphrey |
3/4/5
|
Director |
—
class O/S missing
|
9,444
|
$7,839 | — | 21 Oct 2021 | |
| Martin H. Huber Jr. |
3/4/5
|
PRESIDENT AND HEAD OF R&D |
—
class O/S missing
|
136,500
|
— | — | 16 Aug 2023 | |
| Salvatore Giovine |
3/4/5
|
CHIEF FINANCIAL OFFICER |
—
class O/S missing
|
49,500
|
— | — | 22 Feb 2022 | |
| Edward C. English |
3/4/5
|
PRINCIPAL ACCOUNTING OFFICER |
—
class O/S missing
|
24,000
|
— | — | 01 Jan 2023 | |
| Michael Jay Ross |
3/4/5
|
Director |
—
class O/S missing
|
13,200
|
— | — | 15 Jun 2022 | |
| Tomas J. Heyman |
3/4/5
|
Director |
—
class O/S missing
|
13,200
|
— | — | 12 Jun 2023 |
Institutional Holders of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) as of Q3 2024
As of 30 Sep 2024,
Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) was held by
32 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
15,911,945 shares.
The largest 10 holders included
Bain Capital Life Sciences Investors, LLC, Rock Springs Capital Management LP, MORGAN STANLEY, TAKEDA PHARMACEUTICAL CO LTD, RiverVest Venture Management LLC, FMR LLC, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, Balyasny Asset Management L.P., and RENAISSANCE TECHNOLOGIES LLC.
This page lists
32
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2024 vs Q2 2024 Across Filers
Q2 2024 holders
31
Q3 2024 holders
32
Holder diff
1
| Investor | Q2 2024 Shares | Q3 2024 Shares | Share Diff | Share Chg % | Q2 2024 Value $ | Q3 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.